BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Juventas Therapeutics, Inc. 

10265 Carnegie Avenue

Cleveland  Ohio  44106  U.S.A.
Phone: 216-445-0830 Fax: 216-445-6514


SEARCH JOBS


Industry
Biotechnology






 Company News
Juventas Therapeutics, Inc. Completes Enrollment of Phase II STOP-HF Study of JVS-100 in Patients With Symptomatic Heart Failure 10/28/2013 11:02:51 AM    More...
Juventas Therapeutics, Inc. Hires Biotechnology Veteran Paul Resnick as Vice President of Business Development 1/28/2013 9:54:34 AM    More...
Juventas Therapeutics, Inc. Doses First Patient in Phase II STOP-HF Trial 8/20/2012 10:52:31 AM    More...
Juventas Therapeutics, Inc. Raises $22.2 Million Series B Financing 7/16/2012 8:04:06 AM    More...
Juventas Therapeutics, Inc. Enrolling Patients in Phase IIa STOP-CLI Clinical Trial 5/15/2012 12:29:27 PM    More...
BioCardia and Juventas Therapeutics, Inc. Announce Phase II Development Program of JVS-100 Delivered With the Helical Infusion System to Treat Heart Failure 3/15/2012 6:20:34 AM    More...
Juventas Therapeutics, Inc. Reports One Year Data From Phase I Heart Failure Clinical Trial 1/30/2012 11:04:22 AM    More...
Wound Care Technologies to Acquire Medical Device Distributor Juventas Therapeutics, Inc.; Bryant Gaines Named WNDM COO Effective Immediately 12/1/2011 10:03:33 AM    More...
Juventas Therapeutics, Inc. Demonstrates JVS-100 Delivery to Patients with Heart Failure is Safe and Provides Clinical Benefit 5/25/2011 8:23:01 AM    More...
Juventas Therapeutics, Inc. Completes Successful Phase I Clinical Trial for JVS-100 in Treatment of Patients with Heart Failure; Looks to Raise $25 Million in Series B 4/26/2011 8:01:49 AM    More...
12

//-->